Progesterone therapy to decrease first-trimester spontaneous abortions in previous aborters.

J H Check; J S Chase; K Nowroozi; C H Wu; H G Adelson

PubMed · 2885282

Progesterone therapy to decrease first-trimester spontaneous abortions in previous aborters.

J H Check·J S Chase·K Nowroozi·C H Wu·H G Adelson

Abstract

A study was designed to see if the use of prophylactic progesterone vaginal suppositories (PVS) reduced the risk of spontaneous abortions in women with a history of at least one spontaneous abortion. PVS was employed during the luteal phase to the end of the first trimester. The dosage was initially 50 mg/day, but was increased according to the endometrial biopsy and doubled as soon as pregnancy was established. Only 10 women (10%) aborted, and 8 of these 10 were successful in their next PVS-treated pregnancies. Overall there were 12 losses in 132 pregnancies (9%) in these PVS-treated patients. Forty-two percent of untreated controls aborted (10/24). The results suggest that PVS is effective in reducing the risk of spontaneous abortions in high-risk patients.

Explore related subjects

Abortion, Habitual Corpus Luteum Maintenance Endometrium Female Humans Pessaries Pregnancy Pregnancy Trimester, First Progesterone Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J H Check, J S Chase, K Nowroozi, C H Wu, H G Adelson. Progesterone therapy to decrease first-trimester spontaneous abortions in previous aborters.. https://pubmed.ncbi.nlm.nih.gov/2885282/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Human Chorionic Gonadotrophin (hCG) in the management of recurrent abortion.

Explore the source record for details and available documents.

Abortion, Habitual↗

PubMed1992

Human chorionic gonadotrophin (hCG) in the management of recurrent abortion; results of a multi-centre placebo-controlled study.

An international ten-centre double-blind trial comparing hCG with placebo in the management of habitual abortion was conducted. The dose regime for hCG used was 10,000 IU i.m. on first diagnosis of pregnancy, 5000 IU thence twice weekly to week 12, followed by once weekly up to week 16. Identical ampoulage of placebo was used. Seventy-five patients completed the trial. Thirty-six received hCG and thirty-nine placebo. 83% of the pregnancies on hCG were successful compared with 79% on placebo (P = 0.45). Of the 25 defined as having no cause for their habitual abortion history, 83% on hCG were successful, as were 85% on placebo (P = 0.73). No significant differences were found between the two therapies in terms of delivery weight, placental weight or neonatal Apgar score. This study fails to confirm previous promising placebo-controlled data advocating the use of hCG in habitual abortion.

Abortion, Habitual↗

PubMed1992

[The value of anticardiolipin antibody assessment].

Anticardiolipin antibodies (ACL) are associated with the presence of several clinical conditions. To determine the clinical interest of their evaluation, we reviewed all the results of ACL determinations performed in our laboratory during 1990 and 1991. 266 analyses (232 patients) were carried out. Determinations of IgG and IgM type ACL were performed by ELISA. ACL values were positive or slightly positive in 40% of the analyzed samples. Diagnosis was mentioned as the grounds for 212 requests (186 patients). ACL were positive (> m + 3SD) in about 40% of patients with autoimmune disease or with at least two of the following pathologies: autoimmune disease, venous or arterial thromboembolism, recurrent abortion.

Abortion, Habitual↗